Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Maryland, Baltimore
About this trial
The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.
Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.
Eligibility criteria
Qualifiers
18 years old or older
Patient at University of Maryland Baltimore Washington Medical Center
Willing and able to consent to study procedures listed in the protocol
Ability to speak and understand English
Disqualifiers
Younger than 18 years old
Patient not cared for at University of Maryland Baltimore Washington Medical Center
Unable to consent to study procedures listed in the protocol
Unable to speak or understand English
Trial design
Treatments tested in this trial
- Epigenetic Signature Assay
Treatment groups
750 Participants
are divided into 5 treatment groupsSponsors and collaborators
University of Maryland, Baltimore
Lead sponsor
EPOCH Epigenetics, Inc
Collaborator
Source ClinicalTrials.gov